Rabies intradermal (ID) vaccination is an acknowledged method of immunisation in the prevention of rabies. The literature indicates a suppression of the rabies response when given by the intradermal method in a patient taking chloroquine. In the UK chloroquine/proguanil combination has recently been discontinued. Mefloquine remains available and has structural similarities to chloroquine, but carries no warning of possible suppression of antibody response to the rabies vaccine when given ID. A study of the reports of inhibition of rabies ID by mefloquine highlight a range of advice from no inhibition to 30 days between the final dose of rabies ID and starting mefloquine. The inhibition by chloroquine of rabies vaccine is dependent on cellular concentration, but no study was found to extrapolate warnings to mefloquine. The pharmacodynamics of both chloroquine and mefloquine show an action involving 5HT3 receptors and metabolism by the CYP3A4 pathway. A comparative study is required to evaluate the similarities and differences between the two anti-malarial drugs. In conclusion, the absence of data relating to possible inhibition of rabies ID in a patient taking mefloquine does not necessarily equate to no interaction. A large-scale trial should be completed, and advisory boards should advise caution when using mefloquine and rabies ID until an outcome is confirmed.